Swiss pharma giant Novartis (NOVN: VX) has announced that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab, an inhibitor of interleukin-1beta did not meet its primary endpoint of disease-free survival versus placebo.
The multicenter, randomized, double blind study evaluated the efficacy and safety of the drug as adjuvant treatment in patients with NSCLC stages II-IIIA and IIIB whose margins are free of cancer following surgery.
The disapointing results are not a first for Novartis, as the company has already made several unsuccessful attempts to expand canakinumab to other therapeutic settings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze